In addition to exploring existing drugs for multiple indications, United Therapeutics (UTHR) has been actively investing in research and development (or R&D) programs involving novel technologies. These are targeted toward pulmonary arterial hypertension (or PAH), cancer, and the orphan disease bronchopulmonary dysplasia (or BPD).